Table 2.
RSV | Non-RSV | Controls | |
---|---|---|---|
n | 17 | 11 | 18 |
Convalescence (n) | 7 | 6 | N/A |
Age (months) | 3.5 (0.5–14) | 16 (2–22.4) | 10.5 (0.1–22.4) |
Gender (% of male) | 58.82 | 36.36 | 66.66 |
Family history of atopy (% of subjects) | 23.53 | 9.09 | 0 |
Days of symptoms at the time of sample collection | 5 (2–10) | 4 (2–10) | N/A |
Length of hospitalization (day) | 5 (1–14) | 5 (1–13) | N/A |
Wheezing presence (% of subjects) | 70.59 | 0 | 0 |
Wheezing duration* (days) | 3 (1–10) | N/A | N/A |
O2 saturation (%) | 92 (78–94.6) | >95 | N/A |
Length of O2 supplementation** (days) | 5 (2–7) | N/A | N/A |
Heart rate (beats/minute) | 145 (134–176) | 138+ (130–160) | N/A |
Respiratory frequency (breath/minute) | 48 (36–80) | 33.5+ (24–60) | N/A |
White blood cell count (×109/L) | 9.6 (5.5–17.1) | 19.6 (5.0–36.1) | N/A |
CRP (mg/L) | 4 (0–44.7) | 58.3 (3.4–137) | N/A |
Disease severity score | 7 (5–19) | 5 (3–9) | N/A |
*Only for patients with confirmed wheezing.
**Only for patients that needed O2 supplementation.
+Exact values familiar only for 4 patients, the rest were marked as normal values.